Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
Launched by IMPATIENTS N.V. TRADING AS MYTOMORROWS · Nov 20, 2019
Trial Information
Current as of May 22, 2025
No longer available
Keywords
ClinConnect Summary
UROMUNE® is a mucosal immunotherapy indicated for the prevention of urinary tract infections caused by different pathogens. It works by stimulating the immune system, thus increasing the resistance against recurrent infections. The active substances are 4 inactivated and selected bacterial strains:
* Klebsiella pneumoniae 25%
* Escherichia coli 25%
* Enterococcus faecalis 25%
* Proteus vulgaris 25%
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients suffering recurrent urinary tract infections of diverse etiology.
- Exclusion Criteria:
- • Individuals being allergic to any of the ingredients of UROMUNE®.
- • Pregnancy and breast feeding. There are neither specific studies nor a formal contraindication, the physician should value benefits/risk.
About Impatients N.V. Trading As Mytomorrows
Impatients N.V., operating under the brand name mytomorrows, is a pioneering clinical trial sponsor dedicated to accelerating patient access to innovative therapies. With a focus on bridging the gap between pharmaceutical development and patient needs, mytomorrows collaborates with biopharmaceutical companies to facilitate access to investigational medicines for patients with unmet medical needs. The organization employs a patient-centric approach, leveraging advanced technology and data analytics to streamline the clinical trial process, enhance patient engagement, and ensure that new treatments reach those who need them most efficiently and ethically.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Paris, , France
Berlin, , Germany
Praha, , Czechia
Copenhagen, , Denmark
Brussels, , Belgium
Helsinki, , Finland
Luxembourg, , Luxembourg
Amsterdam, , Netherlands
Oslo, , Norway
Bukarest, , Romania
Bratislava, , Slovakia
Ljubljana, , Slovenia
Stockholm, , Sweden
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials